Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects

Exclusion Criteria

• •Employees of the sponsor or clinical sites.
• •Female subjects.
• •No past or current serious diseases of any organ will be allowed. Exceptions may be non-malignant skin diseases, childhood asthma and other conditions as per the Investigator's discretion and discussed with the Sponsor a priori. History of significant gastrointestinal disease or other significant diseases including cardiac, renal or liver impairment.
• •History of sleep apnea, irregular sleep/wake cycle or working in night shifts.
• •Acute disease state
• •History of hypo/hyperthyroidism or repeated abnormal TSH values at screening or obesity of endocrine origin.
• •History of alcoholism for more than 2 years
• •Positive serology for human immunodeficiency virus (HIV-1/2) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.
• •Positive findings in urine drug screen / alcohol breath test.
• •Participation in another clinical trial within 90 days of the first drug administration.
• •Intake of more than 8-10 cups of coffee and/or tea per day and consumption of methyl xanthine-containing beverages (tea, coffee, cola drinks, chocolate) within 48 hours prior to study.
• •Donation of blood (i.e. 350 ml) within 90 days before Day -1 of the first treatment period.